- Home
- GNTA vs OSRH Comparison
GNTA vs OSRH Comparison
Compare GNTA & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNTA | OSRH |
|---|---|---|
| Founded | 2014 | N/A |
| Country | Italy | United States |
| Employees | 13 | 22 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 17.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GNTA | OSRH |
|---|---|---|
| Price | $1.84 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 750.2K |
| Earning Date | 03-24-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.31 |
| 52 Week High | $10.00 | $1.56 |
Technical Indicators
Market Signals| Indicator | GNTA | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 31.48 |
| Support Level | $1.31 | N/A |
| Resistance Level | $2.12 | $0.45 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 72.46 | 6.16 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.